THINK BIG.

Discovering drug treatments for AIDS. Testing new anticancer agents. Screening Alzheimer's disease therapies... More than 4500 publications attest to the fact that ALZET® micro-osmotic pumps are opening up big opportunities in preclinical research.

These miniature, implantable pumps have proven effective at delivering a wide variety of agents, over sustained periods of time, in mice and rats. They maintain effective levels of short half-life compounds in plasma and tissues, and can be used with a catheter to target delivery to specific organs or tissues.

So, if you want to expand your research possibilities, think about ALZET pumps. For technical data relevant to your work, call (800) 692-2990 or (415) 494-5323 or fax (415) 494-5151. Tell us the compound you want to deliver and where you want it to go. We'll send you published references and technical information to stimulate your thinking.

It just might be the start of something big.
Keep up with the latest developments in

Cancer Research

The Official Journal of the American Association for Cancer Research

Carlo M. Croce, M.D., Editor-in-Chief

Subscribe to Cancer Research—the leading citation source of original studies in cancer research and cancer-related biomedical science. Issued semimonthly, Cancer Research publishes 7,000 pages of important research each year, including the following regular features:

- The most up-to-date articles in basic research and clinical and epidemiological investigations by authors from the United States and more than 30 countries
- Perspectives in Cancer Research, in which leading investigators explore contemporary and at times controversial topics
- Advances in Brief, a rapid communication category for short but definitive, highly significant reports
- Supplemental issues developed from symposia or relevant subjects
- Proceedings of the American Association for Cancer Research, a special annual issue that offers stimulating new research ideas in abstract form

Order Now!

☐ Yes, I want to keep up with the latest developments in Cancer Research: Enter my one-year subscription.

1994 Subscription Rates:

☐ Individual $415 ☐ Institutional $415

Add $60 for delivery outside the U.S. Subscriptions payable in advance (in US currency or equivalent) to:

WAVERLY PRESS, INC./CANCER RESEARCH
428 East Preston Street / Baltimore, MD 21202

NAME

INSTITUTION

ADDRESS

CITY/STATE/ZIP

Allow 8 weeks for receipt of first issue.
Featured on this issue’s cover is the International Agency for Research on Cancer (IARC), established in 1965 by the World Health Assembly as an independently financed organization within the framework of the World Health Organization. The Agency, which is headquartered in Lyon, France, conducts a program of research concentrating particularly on the epidemiology of cancer and the study of potential environmental carcinogens. Its field studies are supplemented by biological and chemical research carried out in the Agency’s laboratories in Lyon and, through collaborative agreements, in research institutions in many countries. The Agency also provides training and educational programs for cancer researchers.

Dr. Lorenzo Tomatis (upper left) has been the Director of the IARC since 1982. One of the first staff members at the Agency, Dr. Tomatis brought his experience and expertise in environmental carcinogenesis and in multigeneration carcinogenicity to the new laboratories. He continued the tradition of the preparation and publication of the “IARC Monographs on the Evaluation of Carcinogenic Risks to Humans,” an important critical reference series that now comprises 58 volumes. These are used extensively by both the international scientific community and the regulatory authorities dealing with environmental carcinogenesis, who require thorough and impartial assessments of scientific data in order to make decisions with often far-reaching economic and social implications.

Under Dr. Tomatis’s outstanding direction, the Agency has moved ahead into the era of molecular epidemiology, a natural development in view of its long-standing commitment to the pursuit of both epidemiological and laboratory research. In parallel, it has taken important steps toward achieving its goal of preventing cancer when causes have been identified; for example, with the Gambia Hepatitis Intervention Study, in which children vaccinated against hepatitis B in their early years will be followed up for life to assess the impact on liver cancer incidence.

Dr. Tomatis will retire from the IARC in January, 1994, and his position will be filled by Dr. Paul Kleihues (lower right), currently Director of the Institute of Neuropathology at the University of Zurich. Professor Kleihues received his M.D. in 1962, and two years later, he assumed a teaching position at the Max-Planck Institute for Brain Research in Cologne as a Research Assistant. From 1976 to 1983, he taught neuropathology at the Institute of Pathology at Freiburg University, and afterwards at the University of Zurich. His major research interest for over twenty years has been the molecular mechanisms of brain carcinogenesis, particularly using nitrosoureas in rodent models. He recently became founding editor of the quarterly journal, Brain Pathology, which is sponsored by the International Society of Neuropathology.

Dr. Tomatis and Dr. Kleihues are both Corresponding Members of the AACR. We are indebted to Dr. Ruggero Montesano for information and photographs.

Sidney Weinhouse